Key Points
- COO Ryan Cohlhepp sold 12,500 shares of Bicara Therapeutics on March 16 at an average price of $19.66 for $245,750, leaving him with 200,641 shares (a 5.86% reduction); including prior sales this year he has sold 33,869 shares for roughly $633,560.50 in proceeds.
- Bicara (NASDAQ:BCAX) trades around $19.32 with a $1.06 billion market cap and a one-year range of $7.80–$20.25, while analysts give an average rating of "Moderate Buy" and an average price target of $30.25.
Bicara Therapeutics Inc. (NASDAQ:BCAX - Get Free Report) COO Ryan Cohlhepp sold 12,500 shares of the stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $19.66, for a total transaction of $245,750.00. Following the completion of the transaction, the chief operating officer directly owned 200,641 shares of the company's stock, valued at $3,944,602.06. This trade represents a 5.86% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.
Ryan Cohlhepp also recently made the following trade(s):
- On Tuesday, March 3rd, Ryan Cohlhepp sold 17,392 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.16, for a total transaction of $315,838.72.
- On Thursday, January 22nd, Ryan Cohlhepp sold 3,828 shares of Bicara Therapeutics stock. The shares were sold at an average price of $18.10, for a total transaction of $69,286.80.
- On Thursday, January 15th, Ryan Cohlhepp sold 149 shares of Bicara Therapeutics stock. The stock was sold at an average price of $18.02, for a total transaction of $2,684.98.
Bicara Therapeutics Price Performance
Shares of NASDAQ:BCAX opened at $19.32 on Wednesday. The company has a market cap of $1.06 billion, a price-to-earnings ratio of -8.62 and a beta of -0.78. The firm has a 50 day simple moving average of $16.90 and a 200 day simple moving average of $16.20. Bicara Therapeutics Inc. has a one year low of $7.80 and a one year high of $20.25.
Analysts Set New Price Targets
Several research firms recently weighed in on BCAX. Wedbush reissued an "outperform" rating and set a $30.00 price objective on shares of Bicara Therapeutics in a report on Tuesday, January 13th. HC Wainwright reaffirmed a "buy" rating on shares of Bicara Therapeutics in a report on Wednesday, January 14th. Mizuho upgraded Bicara Therapeutics to a "hold" rating in a research report on Thursday, December 18th. Citizens Jmp started coverage on Bicara Therapeutics in a research note on Thursday, January 29th. They set a "market perform" rating and a $31.00 price target on the stock. Finally, Citigroup assumed coverage on Bicara Therapeutics in a report on Thursday, January 29th. They set an "outperform" rating on the stock. Six research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $30.25.
Check Out Our Latest Stock Analysis on BCAX
Hedge Funds Weigh In On Bicara Therapeutics
A number of hedge funds have recently modified their holdings of BCAX. Vestal Point Capital LP grew its stake in shares of Bicara Therapeutics by 2.0% in the third quarter. Vestal Point Capital LP now owns 5,100,000 shares of the company's stock worth $80,529,000 after purchasing an additional 100,000 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its position in Bicara Therapeutics by 596.5% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,236,595 shares of the company's stock worth $54,472,000 after purchasing an additional 2,771,868 shares during the last quarter. Janus Henderson Group PLC acquired a new position in Bicara Therapeutics during the 4th quarter worth about $44,484,000. Vanguard Group Inc. grew its position in shares of Bicara Therapeutics by 9.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,200,925 shares of the company's stock valued at $34,753,000 after buying an additional 195,667 shares during the last quarter. Finally, State Street Corp grew its position in shares of Bicara Therapeutics by 179.5% in the 4th quarter. State Street Corp now owns 1,649,537 shares of the company's stock valued at $27,762,000 after buying an additional 1,059,260 shares during the last quarter.
About Bicara Therapeutics
(
Get Free Report)
Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company's research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.
The company's lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
